Accurate ICD-10 coding for metastatic breast cancer is essential for proper billing, treatment planning, and cancer registry reporting. Understanding which codes apply—and when to use them—helps healthcare providers meet documentation standards and ensures patients receive appropriate coverage for stage 4 disease management.
Key Takeaways
- The ICD-10 code for primary breast cancer falls under category C50, while metastatic spread is captured using secondary malignancy codes (C77–C79).
- Both the primary site code and the secondary site code must be reported together for metastatic breast cancer encounters.
- Stage 4 breast cancer coding requires specificity about the anatomical site of metastasis.
- Proper documentation from the treating physician is required to support any metastatic breast cancer diagnosis code.
- Coding guidelines from the ICD-10-CM Official Guidelines must be followed to avoid claim denials and ensure compliance.
Metastatic Breast Cancer ICD-10 Code: C50 and Secondary Malignancy Codes
Metastatic breast cancer ICD-10 code refers to the set of alphanumeric codes used in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) to document breast cancer that has spread beyond the primary site to distant organs or lymph nodes. These codes are used by clinicians, coders, and billing specialists to accurately represent a patient’s diagnosis in electronic health records, insurance claims, and cancer registries. According to the American Cancer Society, metastatic (stage 4) breast cancer accounts for a significant proportion of breast cancer mortality, underscoring the importance of precise documentation.
The primary breast cancer site is coded under category C50, which is further specified by the laterality (right or left breast) and the anatomical subsite within the breast, such as the upper outer quadrant or nipple. For example, C50.911 identifies malignant neoplasm of the unspecified site of the right female breast. However, coding for metastatic disease does not stop at C50. When breast cancer has spread to distant sites, secondary malignancy codes must also be assigned to reflect the full clinical picture.
Secondary malignancy codes fall within the C77–C79 range of ICD-10-CM. These codes identify the sites to which the breast cancer has metastasized. For instance, C79.51 designates secondary malignant neoplasm of bone, and C78.00 designates secondary malignant neoplasm of the lung. The secondary malignant breast cancer ICD-10 code framework requires that both the primary site (C50.x) and the secondary site (C77–C79.x) be reported together on the claim, with sequencing determined by the focus of the encounter.
How to Select the Right Metastatic Breast Cancer ICD-10 Diagnosis Code
Selecting the correct breast cancer with metastasis ICD-10 diagnosis code depends on several clinical factors, including the confirmed primary site, the specific site(s) of metastasis, and the purpose of the clinical encounter. If the patient is being treated primarily for the metastatic site—for example, a bone lesion causing pain—the secondary malignancy code may be sequenced first, followed by the C50 primary site code. Conversely, if the encounter focuses on the primary tumor, C50.x is listed first.
Physicians must explicitly document the relationship between the primary breast tumor and the metastatic lesion. Coders cannot assume metastasis based on clinical notes alone; the attending physician must clearly state that the secondary site represents spread from the breast primary. The ICD-10-CM Official Guidelines for Coding and Reporting specify that the terms “metastatic to,” “direct extension to,” or “spread to” are acceptable documentation to support secondary code assignment.
When multiple metastatic sites are present, each should be coded separately. For example, a patient with breast cancer metastatic to both the liver and the brain would require C78.7 (secondary malignant neoplasm of liver) and C79.31 (secondary malignant neoplasm of brain), in addition to the appropriate C50 code. This level of specificity is required not only for accurate billing but also for complete oncology reporting and research data capture.
ICD-10 Coding for Stage 4 Breast Cancer by Metastatic Site
The ICD-10 code for stage 4 breast cancer does not map to a single universal code. Instead, it is expressed through a combination of the primary C50 code and one or more secondary malignancy codes that reflect where the cancer has spread. ICD-10-CM does not have a standalone “stage 4” designation; clinical staging information is captured through separate Z-codes or TNM classifications used within oncology documentation systems, not through the diagnostic code itself.
The following table summarizes common metastatic sites and their corresponding ICD-10 secondary malignancy codes that are paired with a C50 primary code in stage 4 breast cancer encounters.
| Metastatic Site | ICD-10-CM Code | Code Description |
|---|---|---|
| Bone | C79.51 | Secondary malignant neoplasm of bone |
| Lung | C78.00 | Secondary malignant neoplasm of unspecified lung |
| Liver | C78.7 | Secondary malignant neoplasm of liver and intrahepatic bile duct |
| Brain | C79.31 | Secondary malignant neoplasm of brain |
| Lymph nodes (distant) | C77.x | Secondary and unspecified malignant neoplasm of lymph nodes (site-specific) |
| Skin | C79.2 | Secondary malignant neoplasm of skin |
Breast cancer metastasizes most commonly to bone, lung, liver, and brain. Data from the National Cancer Institute’s SEER program indicate that bone is the most frequent first site of distant metastasis in breast cancer, occurring in approximately 50–70% of patients with metastatic disease. Accurate site-specific coding ensures that treatment-related claims—such as bisphosphonate therapy for bone metastasis—are properly supported by the diagnosis on file.
When the metastatic site is not yet confirmed but is clinically suspected, coding guidelines direct providers to use codes for signs and symptoms rather than unconfirmed diagnoses, unless the clinical context occurs in an inpatient setting where uncertain diagnoses may be coded as if confirmed. Outpatient encounters require confirmed diagnoses to assign metastatic codes.
Metastatic Breast Cancer ICD-10 Billing: Documentation and Coding Guidelines
The metastatic breast cancer billing code ICD-10 process involves more than simply selecting codes from a list. Compliance with the ICD-10-CM Official Guidelines, payer-specific policies, and CMS documentation requirements is essential for clean claim submission. Inadequate documentation remains one of the leading causes of claim denials in oncology billing, making physician-coder collaboration a critical part of the revenue cycle.
For billing purposes, the principal diagnosis should reflect the condition chiefly responsible for the encounter. In a chemotherapy infusion visit for metastatic breast cancer, the Z51.11 code (encounter for antineoplastic chemotherapy) is sequenced first, followed by the C50 primary code and then any applicable secondary malignancy codes. This sequencing follows CMS guidelines for encounters focused on treatment of the malignancy rather than the malignancy itself as the reason for admission.
Coders should also be aware of the distinction between coding an active malignancy versus a personal history of cancer. Once a patient has completed treatment and the cancer is no longer being actively treated, the appropriate code shifts to Z85.3x (personal history of malignant neoplasm of breast). However, for patients with ongoing metastatic disease receiving systemic therapy, immunotherapy, or radiation, the active malignancy codes remain appropriate and must be reported at every relevant encounter.
- Always assign both the primary breast cancer code (C50.x) and the secondary site code(s) for metastatic encounters.
- Sequence codes according to the focus of the clinical encounter and applicable ICD-10-CM guidelines.
- Do not code suspected metastasis in outpatient settings without physician confirmation in the clinical documentation.
- Update codes at each encounter to reflect current disease status, including newly identified metastatic sites.
- Use Z-codes for treatment encounters (e.g., Z51.11) when the purpose of the visit is chemotherapy or radiation administration.
Consistent and precise documentation supports not only reimbursement but also population-level cancer surveillance. The CDC and state cancer registries rely on ICD-10-CM codes to track incidence, metastatic patterns, and treatment outcomes for breast cancer at a national level. Accurate coding, therefore, serves both individual patient care and broader public health objectives.
Frequently Asked Questions
Can a single ICD-10 code represent both the primary breast tumor and its metastasis?
No. ICD-10-CM requires separate codes for the primary site and each secondary (metastatic) site. The C50 category covers the primary breast malignancy, while C77–C79 codes identify where the cancer has spread. Both must be reported together on the claim to accurately represent the patient’s diagnosis. Reporting only one code may result in incomplete documentation, claim denials, or audits.
Does ICD-10-CM have a specific code that indicates “stage 4” breast cancer directly?
ICD-10-CM does not include a dedicated code labeled “stage 4.” Clinical staging is documented separately in the medical record using TNM classification or oncology staging tools. The stage 4 designation is inferred through the combination of a C50 primary code and one or more secondary malignancy codes (C77–C79), which together indicate distant metastatic spread consistent with stage 4 disease.
When should a coder switch from an active malignancy code to a personal history code for breast cancer?
The transition occurs when the treating physician documents that the cancer has been eradicated or is no longer under active treatment. For metastatic breast cancer, this is relatively uncommon, as most patients continue long-term systemic therapy. Active malignancy codes should be used for all encounters where treatment is ongoing. The personal history code Z85.3x is appropriate only after confirmed remission with no ongoing cancer-directed therapy.
